BioAge Labs, Retro Biosciences, and Life Biosciences all have human data now. It is not the same kind of evidence, and the clearest exploratory signal comes from just three patients.
Three longevity programs now have what gets called human data. A biomarker trial, a safety study, and a three-patient eye trial are not the same thing, and only the eye trial has produced an exploratory clinical signal.
By Rabbt | November 2, 2026
3D illustration shows the detailed anatomy of a eukaryotic human cell.
Longevity biotech has a milestone problem. Three companies now have what gets described as human data, and coverage can treat that phrase as a single finish line. It is not. A randomized safety study in healthy volunteers, a biomarker readout in a controlled trial, and an open-label signal in three patients are different kinds of evidence collected for different purposes. In this comparison, the clearest exploratory signal comes from the three-patient study, not the best-funded company. Where each program actually stands says more about the field's progress than its funding total does.
Why Aging Has No Clinical Trials of Its Own
The U.S. Food and Drug Administration does not recognize aging as a disease. So no company can run a trial that treats aging itself as the endpoint. Every longevity company has to enter the clinic through a specific, approvable condition instead: elevated cardiovascular inflammation, Alzheimer's disease, glaucoma. That choice of door shapes what the resulting data can and cannot show. BioAge Labs, Retro Biosciences, and Life Biosciences have each picked a different door, and their earliest human data reflect three different kinds of evidence collected for three different reasons. Altos Labs is the field's largest funded entrant. It launched in January 2022 with about three billion dollars in committed capital. As of this issue's research, it has not disclosed a named clinical candidate or a company-sponsored human trial. It also has not filed an Investigational New Drug application, called an IND, the FDA filing required before a company can test a drug in people [1]. NewLimit, another reprogramming-focused company, closed a $435 million financing round in June 2026. It plans to put its first reprogramming medicine into human trials in 2027 [2]. Funding size and clinical progress are separate stories in this sector, even when coverage treats them as one.
BioAge Labs
Public, NASDAQ: BIOA. Headquartered in Emeryville, California. Founded 2015. Cash and marketable securities of approximately $381.3 million as of June 30, 2026 [3].
BioAge Labs is running one drug as two separate experiments that measure different things. BGE-102 is an oral, once-daily, brain-penetrant inhibitor of NLRP3. NLRP3 is a protein complex inside immune cells that, when activated, drives much of the body's low-grade inflammation. BioAge says its discovery platform identified NLRP3 by comparing molecular data across a cohort of long-lived people, in whom lower NLRP3 activity tracked with greater longevity.
The company's Phase 1 data, reported on April 21, 2026, found that BGE-102 produced a median hsCRP reduction of 86 percent from baseline. The release reported that reduction at day 21 for the 60 mg dose and day 14 for the 120 mg dose, because the doses were tested for different lengths of time [4]. High-sensitivity C-reactive protein, or hsCRP, is a standard blood marker of systemic inflammation. By those same time points, 87 percent of participants on the 60 mg dose, 13 of 15, and 93 percent on the 120 mg dose, 13 of 14, had their hsCRP fall below the clinical threshold of 2 milligrams per liter [4]. BioAge's release did not report a placebo comparison for these figures. The result is a biomarker readout from a small, single-arm study. It shows a measurable effect on inflammation. It does not, on its own, show that the drug treats a disease.
BioAge is now running two Phase 2 trials of BGE-102 that test the molecule in structurally different ways. QUELL-CV finished enrolling roughly 160 adults with obesity and elevated inflammation in September 2026 [5]. It is a randomized, placebo-controlled trial comparing three doses against placebo, still measuring hsCRP and related biomarkers. QUELL-DME began dosing the same month [5]. It moves BGE-102 into diabetic macular edema and changes the endpoint entirely: the primary measure is change in best-corrected visual acuity, a direct test of whether patients can see better, at week 12. One molecule, one company. Two trials, two different definitions of success.
BioAge depends on two outside relationships for anything beyond BGE-102. Novartis is paying BioAge to help find new drug targets where aging biology and exercise biology meet. Eli Lilly's ExploR&D unit is doing something similar: paying BioAge to find antibodies against metabolic aging targets the company's platform has flagged. Both partnerships were still moving forward as of BioAge's most recent public update [3]. Lilly was also BioAge's development partner on its one clinical failure to date. Lilly's Chorus unit partnered on STRIDES, the Phase 2 trial of an earlier BioAge drug, azelaprag, that BioAge stopped in late 2024 after a liver-related safety signal and discontinued the following January [6]. Azelaprag and BGE-102 are different molecules with different mechanisms, and BioAge has reported no similar finding for BGE-102. The same partner therefore appears on both sides of BioAge's history: as a development partner on one failure and as an ongoing discovery collaborator.
What to watch: whether QUELL-CV's placebo-controlled readout confirms the Phase 1 biomarker effect at a larger scale. BioAge guided the readout for the second half of 2026, but it had not been reported as of this issue's publish date. BioAge has not announced a confirmed date for its third-quarter earnings call. Third-party estimates range from November 5 to November 9, days after this issue's publish date. If the earnings release includes QUELL-CV's topline result, it would be the first controlled test of whether BGE-102's inflammatory effect holds up outside a small Phase 1 study. That makes QUELL-CV a near-term trigger for this read.
Retro Biosciences
Private. Headquartered in Redwood City, California. Clinical-stage since December 2025.
Retro Biosciences draws attention for its reprogramming ambitions and its OpenAI connection. Its actual human trial is neither of those things. RTR242, the company's only clinical candidate, is a conventional oral small molecule meant to restore autophagy, the cell's internal waste-clearance system. Its first target indication is early-onset Alzheimer's disease. The Phase 1 study testing it is a randomized, double-blind, placebo-controlled trial in healthy volunteers in Adelaide, Australia, not in Alzheimer's patients [7]. Eight participants were dosed in the trial's first cohort in mid-December 2025. The design runs five cohorts of single ascending doses, from 50 to 800 milligrams, with six participants on drug and two on placebo in each cohort [7].
Retro's CEO, Joe Betts-LaCroix, told an audience at a biotech industry summit in May 2026 that the trial was going well and that researchers had not seen any dose-limiting toxicities [8]. He said he expected to release some data around August [8]. No dataset has surfaced in the sources reviewed for this issue. The same week, Retro announced the initial close of a new financing round at a reported $1.8 billion valuation [8]. A valuation is not an amount raised, and it is not a measure of clinical progress.
What to watch: whether Retro publishes a dataset from its healthy-volunteer safety study, rather than another verbal update, before the company moves toward dosing patients with Alzheimer's disease.
Life Biosciences
Private. Headquartered in Boston, Massachusetts. Clinical-stage since June 2026.
Life Biosciences has produced the clearest exploratory clinical signal among these three companies. It comes from only three patients. ER-100 delivers three reprogramming factors, OCT4, SOX2, and KLF4, known together as OSK, into the eye using a modified virus. A course of oral doxycycline then switches them on. The FDA cleared the company to test ER-100 in people in January 2026. The first patient was dosed on June 9, 2026, the field's first disclosed human dose of a partial epigenetic reprogramming therapy [9].
On October 8, 2026, Life Biosciences reported interim data from the first three participants, all with open-angle glaucoma, at the trial's lowest dose [10]. The company says treatment was well tolerated through day 56, with no dose-limiting toxicities or serious adverse events [10]. An independent safety board recommended moving to a higher dose [10]. Two of the three participants showed improvement on a standard visual field test, with at least 28 percent of tested points improving by more than 4 decibels [10]. That is a company-reported exploratory signal. It is also based on three people, one study arm, no control group, and a test that can vary from one session to the next even without treatment.
What to watch: whether the signal persists at the second dose level and in a larger group of participants.
| Company | Role in Stack | Structural Position | Key Dependency | What to Watch |
|---|---|---|---|---|
| BioAge Labs | Public anchor, NLRP3 inhibitor across two indications | Same molecule tested as both a biomarker trial and a visual-acuity trial | Two active pharma collaborations, Novartis and Lilly ExploR&D, for anything past BGE-102 | Whether QUELL-CV's controlled readout confirms the Phase 1 biomarker effect |
| Retro Biosciences | Private, autophagy-focused safety study | Healthy-volunteer Phase 1 safety trial, no published dataset | A published dataset, rather than further verbal updates, to move the story beyond a safety update | Whether a full dataset appears before dosing shifts toward Alzheimer's patients |
| Life Biosciences | Private, early human reprogramming result | Clearest exploratory clinical signal among the three, based on three patients | Confirming the signal at a higher dose and in more patients | Whether the visual-field improvement persists at Dose Level 2 |
The Honest Tension
Every human dataset in this piece is a safety, biomarker, or early exploratory result. None of it shows that any of these three drugs changes a confirmed clinical outcome. Entering the clinic through a specific disease, rather than through aging itself, could turn each of these programs into an ordinary single-indication biotech story. At that point, longevity would function more as a framing category than as a distinct clinical development model. BioAge's own history shows the risk: azelaprag cleared Phase 1 testing and still failed in Phase 2 [6]. The clearest signal in this comparison still rests on three people.
Rabbt Intelligence Note
A structured Research File on BioAge Labs would map BGE-102's two Phase 2 programs, the hsCRP-driven QUELL-CV trial and the visual-acuity-driven QUELL-DME trial, against each other. It would flag QUELL-CV's still-unreported topline as the change trigger most likely to shift this picture, since it is the first controlled test of whether the Phase 1 biomarker effect holds. The Relationship Graph would show that Eli Lilly sits on both sides of BioAge's history, as the development partner on the failed STRIDES trial and as a continuing discovery collaborator through Lilly ExploR&D, a connection none of the sources reviewed for this issue framed together. The open question is whether a single NLRP3 inhibitor can show a real benefit in two conditions that look nothing alike, a test that could help distinguish aging biology from ordinary single-disease drug development.
This is editorial content. Rabbt is not a registered investment advisor and does not provide investment recommendations.
This issue reflects structural analysis and figures verified as of its publish date. The frontier economy moves quickly: funding rounds close, valuations shift, contracts get renegotiated, and timelines change. Details in this issue may no longer be current by the time you are reading it. Treat this as a structural snapshot, not a live feed, and verify anything time-sensitive independently before acting on it.
Sources
[1] Longevity.Technology. "Is Altos Labs gearing up for clinical trials?" August 2025. https://longevity.technology/news/is-altos-labs-gearing-up-for-clinical-trials/
[2] DeAngelis, Allison. "Longevity startup NewLimit announces $435 million clinical trial financing." STAT News, June 2, 2026. https://www.statnews.com/2026/06/02/longevity-startup-newlimit-announces-435-million-clinical-trial-financing/
[3] BioAge Labs, Inc. "BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates." August 5, 2026. https://ir.bioagelabs.com/node/8016/pdf
[4] BioAge Labs, Inc. "BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP." April 21, 2026. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-reports-positive-phase-1-data-bge-102-novel-oral-nlrp3
[5] BioAge Labs, Inc. "BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema." September 8, 2026. https://www.biospace.com/press-releases/bioage-labs-announces-first-participant-dosed-in-quell-dme-a-phase-2-trial-of-bge-102-a-novel-oral-nlrp3-inhibitor-in-diabetic-macular-edema
[6] BioAge Labs, Inc., via Barchart. "BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs." January 28, 2025. https://www.barchart.com/story/news/30641873/bioage-labs-announces-company-updates-on-apj-nlrp3-and-platform-programs
[7] Fight Aging (fightaging.org). "Retro Biosciences Starts a Safety Trial for an Autophagy Promoter." January 2026. https://www.fightaging.org/?p=66091 (trial design per Australia and New Zealand Clinical Trials Registry, ACTRN12625001274460)
[8] DeAngelis, Allison. STAT News, May 22, 2026. https://www.statnews.com/2026/05/22/retro-biosciences-longevity-valuation
[9] AI Weekly. "Life Biosciences Doses First ER-100 Phase 1 Patient." June 2026. https://aiweekly.co/alerts/life-biosciences-doses-first-er-100-phase-1-patient
[10] Life Biosciences, Inc. "Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies." October 8, 2026. https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/